Topical Testosterone for Breast Cancer Patients with Vaginal Atrophy Related to Aromatase Inhibitors: A Phase I/II Study

2011156 citationsJournal Articlebronze Open Access

Authors

Sabrina Witherby · Brown University

Julia V. Johnson · University of Massachusetts Chan Medical School

Laurence M. Demers · Pennsylvania State University

Sharon Mount · University of Vermont

Benjamin Littenberg · University of Vermont

Charles D. MacLean · University of Vermont

Marie Wood

Abstract

A 4-week course of vaginal testosterone was associated with improved signs and symptoms of vaginal atrophy related to AI therapy without increasing estradiol or testosterone levels. Longer-term trials are warranted.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Oncologist

Volume 16, Issue 4, pp. 424-431

DOI: 10.1634/theoncologist.2010-0435

Field-Weighted Citation Impact: 6.81

Command Palette